These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 29316844)
1. PI3K pathway and Bcl-2 family. Clinicopathological features in prostate cancer. Torrealba N; Rodriguez-Berriguete G; Fraile B; Olmedilla G; Martínez-Onsurbe P; Sánchez-Chapado M; Paniagua R; Royuela M Aging Male; 2018 Sep; 21(3):211-222. PubMed ID: 29316844 [TBL] [Abstract][Full Text] [Related]
2. TGF-β/PI3K/AKT/mTOR/NF-kB pathway. Clinicopathological features in prostate cancer. Torrealba N; Vera R; Fraile B; Martínez-Onsurbe P; Paniagua R; Royuela M Aging Male; 2020 Dec; 23(5):801-811. PubMed ID: 30973040 [TBL] [Abstract][Full Text] [Related]
3. Clinical significance of both tumor and stromal expression of components of the IL-1 and TNF-α signaling pathways in prostate cancer. Rodríguez-Berriguete G; Sánchez-Espiridión B; Cansino JR; Olmedilla G; Martínez-Onsurbe P; Sánchez-Chapado M; Paniagua R; Fraile B; Royuela M Cytokine; 2013 Nov; 64(2):555-63. PubMed ID: 24063999 [TBL] [Abstract][Full Text] [Related]
4. Expression of several cytokines in prostate cancer: Correlation with clinical variables of patients. Relationship with biochemical progression of the malignance. Torrealba N; Rodríguez-Berriguete G; Fraile B; Olmedilla G; Martínez-Onsurbe P; Guil-Cid M; Paniagua R; Royuela M Cytokine; 2017 Jan; 89():105-115. PubMed ID: 27527810 [TBL] [Abstract][Full Text] [Related]
5. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer. Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749 [TBL] [Abstract][Full Text] [Related]
6. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients. Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093 [TBL] [Abstract][Full Text] [Related]
7. The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer. Kim KH; Han KS; Kim KH; Kim DK; Koo KC; Rha KH; Choi YD; Hong SJ Urol Oncol; 2015 Sep; 33(9):383.e17-22. PubMed ID: 26004165 [TBL] [Abstract][Full Text] [Related]
8. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117 [TBL] [Abstract][Full Text] [Related]
9. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495 [TBL] [Abstract][Full Text] [Related]
10. Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer. Li R; Erdamar S; Dai H; Wheeler TM; Frolov A; Scardino PT; Thompson TC; Ayala GE Hum Pathol; 2007 Oct; 38(10):1501-7. PubMed ID: 17597184 [TBL] [Abstract][Full Text] [Related]
11. PTEN/PI3K/AKT protein expression is related to clinicopathological features and prognosis in breast cancer with axillary lymph node metastases. Wang LL; Hao S; Zhang S; Guo LJ; Hu CY; Zhang G; Gao B; Zhao JJ; Jiang Y; Tian WG; Wang J; Luo DL Hum Pathol; 2017 Mar; 61():49-57. PubMed ID: 27864123 [TBL] [Abstract][Full Text] [Related]
12. Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-kappaB signalling pathway and prognostic significance in prostate cancer. Koumakpayi IH; Le Page C; Mes-Masson AM; Saad F Br J Cancer; 2010 Mar; 102(7):1163-73. PubMed ID: 20216540 [TBL] [Abstract][Full Text] [Related]
13. Expression of Bcl-2 and Bax in advanced or metastatic prostate carcinoma. Anvari K; Seilanian Toussi M; Kalantari M; Naseri S; Karimi Shahri M; Ahmadnia H; Katebi M; Sedighi Pashaki A; Dayani M; Broumand M Urol J; 2012; 9(1):381-8. PubMed ID: 22395836 [TBL] [Abstract][Full Text] [Related]
14. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Satoh T; Yang G; Egawa S; Addai J; Frolov A; Kuwao S; Timme TL; Baba S; Thompson TC Cancer; 2003 Mar; 97(5):1225-33. PubMed ID: 12599229 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of inhibitors of apoptosis proteins (IAPs) and caspases in prostate cancer: caspase-3 forms and XIAP predict biochemical progression after radical prostatectomy. Rodríguez-Berriguete G; Torrealba N; Ortega MA; Martínez-Onsurbe P; Olmedilla G; Paniagua R; Guil-Cid M; Fraile B; Royuela M BMC Cancer; 2015 Oct; 15():809. PubMed ID: 26507126 [TBL] [Abstract][Full Text] [Related]
16. High expression of KLK14 in prostatic adenocarcinoma is associated with elevated risk of prostate-specific antigen relapse. Rabien A; Fritzsche F; Jung M; Diamandis EP; Loening SA; Dietel M; Jung K; Stephan C; Kristiansen G Tumour Biol; 2008; 29(1):1-8. PubMed ID: 18497543 [TBL] [Abstract][Full Text] [Related]
17. Reduced Connexin 43 expression is associated with tumor malignant behaviors and biochemical recurrence-free survival of prostate cancer. Xu N; Chen HJ; Chen SH; Xue XY; Chen H; Zheng QS; Wei Y; Li XD; Huang JB; Cai H; Sun XL Oncotarget; 2016 Oct; 7(41):67476-67484. PubMed ID: 27623212 [TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer. Saito T; Hara N; Kitamura Y; Komatsubara S Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541 [TBL] [Abstract][Full Text] [Related]
19. Coexpression of aPKCλ/ι and IL-6 in prostate cancer tissue correlates with biochemical recurrence. Ishiguro H; Akimoto K; Nagashima Y; Kagawa E; Sasaki T; Sano JY; Takagawa R; Fujinami K; Sasaki K; Aoki I; Ohno S; Kubota Y; Uemura H Cancer Sci; 2011 Aug; 102(8):1576-81. PubMed ID: 21535317 [TBL] [Abstract][Full Text] [Related]
20. Tumor volume, surgical margin, and the risk of biochemical recurrence in men with organ-confined prostate cancer. Song C; Kang T; Yoo S; Jeong IG; Ro JY; Hong JH; Kim CS; Ahn H Urol Oncol; 2013 Feb; 31(2):168-74. PubMed ID: 21719325 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]